Alan Pollack is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Suite 1500
Miami, FL 331361002
Telephone
305-243-4916Registry record last updated 31 Jan 2013.
Clinical trials
- Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
Sponsor: University of Miami
- Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management
Sponsor: University of Miami
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ambu Inc.Program year20242 payments
- Siemens Medical Solutions USA, Inc.Program year20231 payment
- Boston Scientific CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
58.5%alpha-Adrenergic Blocker58.5%Tamsulosin Hcl100%Part D≥15 patientsCancer & immunology
41.5%Gonadotropin Releasing Hormone Receptor Antagonist41.5%Orgovyx100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Longitudinal Imaging and Liquid Biopsy Markers of Prostate Cancer Radiotherapy Outcomes
University of Miami School of Medicine
FY2026$528,207R01CA294824 - The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer Detection
University of Miami School of Medicine
FY2026$411,697R01CA272766 - Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness
University of Miami School of Medicine
FY2026$351,131U01CA271400
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”